EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Five-year outcomes of the early-generation Intrepid transapical transcatheter mitral valve replacement system

Gilbert H L Tang, Vivek Rajagopal, Paul Sorajja, Tanvir Bajwa, Robert Gooley, Antony Walton, Thomas Modine, Martin K Ng, Mathew R Williams, Alan Zajarias, David Hildick-Smith, Didier Tchétché und 15 weitere

EuroIntervention · 2026-02 · 22 (3) · e172-e182

DOI: 10.4244/eij-d-25-01133 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift EuroIntervention, 2026-02. Verfasst von Gilbert H L Tang und 26 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Health System, New York, NY, USA. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Heart Valve Prosthesis Implantation, Mitral Valve, Heart Valve Prosthesis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Transcatheter mitral valve replacement (TMVR) offers a potential treatment option for select patients with mitral regurgitation (MR) deemed unsuitable for surgery or transcatheter repair, but data are limited on its long-term durability and performance. AIMS: We evaluated 5-year outcomes from the global Pilot Study with the Intrepid transapical (TA) TMVR system. METHODS: This multicentre, single-arm study evaluated the early-generation Intrepid TA system in patients with symptomatic ≥moderate-severe MR at high risk for mitral valve (MV) surgery. Echocardiograms and clinical events were independently adjudicated, and patients were followed for up to 5 years. RESULTS: Ninety-five patients were enrolled at 21 sites between 2015 and 2019. The mean age was 74.0±9.2 years, 43.2% of patients were female, the mean Society of Thoracic Surgeons Predicted Risk of Mortality score was 6.5±4.8%, 57.9% had prior heart failure hospitalisation (HFH), and 88.4% were in New York Heart Association (NYHA) Functional Class III/IV. Secondary MR was present in 78.7%, and 76.6% had a left ventricular ejection fraction ≤50%. Up to 5 years, all-cause mortality was 66.7% and HFH was 55.4%, with one 30-day MV reintervention (1.1%). Haemodynamic valve deterioration occurred in 1.4%, the median MV mean gradient remained stable at 3.6 mmHg (first and third quartiles: 3.0, 4.8 mmHg), ≤mild MR was present in 100% of patients, and no patient experienced paravalvular leak. NYHA Functional Class I/II was maintained in 84.6%. CONCLUSIONS: In this 5-year follow-up of the early-generation Intrepid TA TMVR system, we observed sustained MR reduction, durable haemodynamic valve performance, and improved functional status among survivors. The APOLLO (ClinicalTrials.gov: NCT03242642) and APOLLO-EU (NCT05496998) trials using the transfemoral Intrepid system will further determine the role of TMVR in managing this high-risk patient population. CLINICALTRIALS: gov: NCT02322840.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve InsufficiencyHeart Valve Prosthesis ImplantationMitral ValveHeart Valve ProsthesisCardiac CatheterizationHumansFemaleAgedMaleTreatment OutcomeAged, 80 and overPilot ProjectsTime Factors

Autor:innen und Institutionen

  • Mount Sinai Health System, New York, NY, USA.
  • Piedmont Heart Institute, Atlanta, GA, USA.
  • Abbott Northwestern Hospital, Minneapolis, MN, USA.
  • Aurora St. Luke's Medical Center, Milwaukee, WI, USA.
  • Victorian Heart Hospital and Victorian Heart Institute, Melbourne, Australia.
  • Cardiology Department, The Alfred, Melbourne, Australia.

Zitieren

APA

Tang, G. H. L., Rajagopal, V., Sorajja, P., Bajwa, T., Gooley, R., Walton, A., Modine, T., Ng, M. K., Williams, M. R., Zajarias, A., Hildick-Smith, D., Tchétché, D., Spargias, K., Rajani, R., Bapat, V. N., De Backer, O., Blackman, D., McCarthy, P., Laine, M., …, & Reardon, M. J. (2026). Five-year outcomes of the early-generation Intrepid transapical transcatheter mitral valve replacement system. EuroIntervention, 22(3), e172-e182. https://doi.org/10.4244/eij-d-25-01133

Vancouver

Tang GHL, Rajagopal V, Sorajja P, Bajwa T, Gooley R, Walton A, et al. Five-year outcomes of the early-generation Intrepid transapical transcatheter mitral valve replacement system. EuroIntervention. 2026;22(3):e172-e182. doi:10.4244/eij-d-25-01133

BibTeX
@article{Tang2026,
  author = {Tang, Gilbert H L and Rajagopal, Vivek and Sorajja, Paul and Bajwa, Tanvir and Gooley, Robert and Walton, Antony and Modine, Thomas and Ng, Martin K and Williams, Mathew R and Zajarias, Alan and Hildick-Smith, David and Tchétché, Didier and Spargias, Konstantinos and Rajani, Ronak and Bapat, Vinayak N and De Backer, Ole and Blackman, Daniel and McCarthy, Patrick and Laine, Mika and Jain, Renuka and Martin, Randolph and Thaden, Jeremy J and Marka, Nicholas A and Mack, Michael and Adams, David H and Leon, Martin B and Reardon, Michael J},
  title = {Five-year outcomes of the early-generation Intrepid transapical transcatheter mitral valve replacement system},
  journal = {EuroIntervention},
  year = {2026},
  volume = {22},
  number = {3},
  pages = {e172--e182},
  doi = {10.4244/eij-d-25-01133}
}
Kostenlos starten →